KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $128.2 million.

  • West Pharmaceutical Services' Income from Continuing Operations rose 7.81% to $128.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $479.3 million, marking a year-over-year increase of 27.2%. This contributed to the annual value of $479.3 million for FY2025, which is 27.2% up from last year.
  • West Pharmaceutical Services' Income from Continuing Operations amounted to $128.2 million in Q4 2025, which was up 7.81% from $137.9 million recorded in Q3 2025.
  • West Pharmaceutical Services' 5-year Income from Continuing Operations high stood at $183.0 million for Q2 2022, and its period low was $86.4 million during Q1 2025.
  • For the 5-year period, West Pharmaceutical Services' Income from Continuing Operations averaged around $137.0 million, with its median value being $134.0 million (2023).
  • As far as peak fluctuations go, West Pharmaceutical Services' Income from Continuing Operations surged by 12075.72% in 2021, and later crashed by 3243.06% in 2022.
  • Over the past 5 years, West Pharmaceutical Services' Income from Continuing Operations (Quarter) stood at $147.7 million in 2021, then crashed by 32.43% to $99.8 million in 2022, then skyrocketed by 33.97% to $133.7 million in 2023, then fell by 4.19% to $128.1 million in 2024, then increased by 0.08% to $128.2 million in 2025.
  • Its Income from Continuing Operations stands at $128.2 million for Q4 2025, versus $137.9 million for Q3 2025 and $126.8 million for Q2 2025.